Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors

The programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) signaling pathway is an important mechanism in tumor immune escape, and expression of PD-L1 on tumor cells has been reported more frequently. However, accumulating evidence suggests that PD-1/PD-L1 is also widely expressed on...

Full description

Bibliographic Details
Published in:	Cancer Biology & Medicine
Main Authors:	Min Liu, Qian Sun, Feng Wei, Xiubao Ren
Format:	Article
Language:	English
Published:	China Anti-Cancer Association 2020-08-01
Subjects:	immune cell immunotherapy programmed cell death ligand 1 programmed cell death-1 solid tumor
Online Access:	http://www.cancerbiomed.org/index.php/cocr/article/view/1670

Similar Items

Assessment of programmed cell death 1 and its programmed cell death ligand 1 levels in vitiligo
by: Hanan R. Nada, et al.
Published: (2025-01-01)

Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
by: Qiang Liu, et al.
Published: (2017-01-01)

Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma
by: Yuan Gao, et al.
Published: (2017-07-01)

Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells
by: Rachel M. Gibbons Johnson, et al.
Published: (2017-08-01)

Association of disease activity with programmed cell death 1 and its ligand programmed cell death ligand 1 expressions in lupus patients
by: Eman Eissa, et al.
Published: (2022-01-01)

Expression of programmed death-ligand 1 and programmed death-1 in patients with extramammary paget's disease
by: Hiroyuki Goto, et al.
Published: (2021-01-01)

Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy
by: Yiming Wang, et al.
Published: (2018-03-01)

Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: a comprehensive systematic review
by: Gilbert Lazarus, et al.
Published: (2019-10-01)

Programmed death-1 and programmed death ligand-1 blockade for advanced urothelial carcinoma
by: Jhe-Cyuan Guo, et al.
Published: (2019-01-01)

A comparative study to assess the increased expression of programmed cell death-1 (PD1) and programmed cell death- ligand-1 (PDL1) in oral potentially malignant disorders and oral squamous cell carcinoma
by: Sonalika Srivastava, et al.
Published: (2023-01-01)

Programmed death receptor-1/programmed death-ligand 1 inhibitors: Clinical progress and biomarker exploration in gastric cancer
by: Jin Shi, et al.
Published: (2024-10-01)

Anti-programmed death ligand 1 (PD-L1) inhibitors in metastatic gastric cancer
by: Jang Ho Cho, et al.
Published: (2017-12-01)

Programmed death ligand 1 (PD-L1) expression in gastric cancer: literature review
by: T. N. Sotnikova, et al.
Published: (2023-07-01)

A study on expression of programmed death ligand-1 in small cell lung carcinoma and correlation with clinicopathological parameters
by: Sudha Sudha, et al.
Published: (2024-03-01)

Programmed cell death-1 blockade in kidney carcinoma may induce eosinophilic granulomatosis with polyangiitis: a case report
by: Masanori Harada, et al.
Published: (2021-01-01)

Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1
by: Yu-Tzu Tai, et al.
Published: (2018-08-01)

Research progress on programmed death receptor 1/ ligand 1 inhibitor in immunotherapy of head and neck squamous cell carcinoma
by: ZENG Fei, et al.
Published: (2021-10-01)

Programmed death-1 (PD-1) ligand 1 and PD-1 ligand 2 expressions and their clinical relevance in colorectal cancer
by: Jee Hyun Ahn, et al.
Published: (2017-12-01)

Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis
by: Feng Xian, et al.
Published: (2023-04-01)

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
by: Joon Seon Song, et al.
Published: (2019-10-01)

Implications of Programmed Death Ligand-1 Positivity in Non-Clear Cell Renal Cell Carcinoma
by: Juan Chipollini, et al.
Published: (2018-10-01)

Widespread Hypertrophic Lichen Planus following Programmed Cell Death Ligand 1 Blockade
by: Caitlyn N. Myrdal, et al.
Published: (2020-06-01)

PD-L1 and PD-1 in immune regulation and their implications in blood cancers
by: Parisa Shiri Aghbash, et al.
Published: (2024-10-01)

Programmed cell death-ligand 1 expression in correlation with human papillomavirus status in cervical cancer: A 1-year retrospective study
by: Kaumudi Konkay, et al.
Published: (2025-01-01)

Real-World Treatment Patterns and Outcomes Among Patients With Metastatic NSCLC Previously Treated With Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Inhibitors
by: Savreet Bains, MS, et al.
Published: (2022-02-01)

Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis
by: Xiaoying Sun, et al.
Published: (2019-06-01)

Immunohistochemical Expression of Programmed Death Ligand-1 in Tumour Milieu of Oral Cancer
by: Moomal Aslam Khan, et al.
Published: (2020-01-01)

Risk of interstitial lung disease with the use of programmed cell death 1 (PD-1) inhibitor compared with programmed cell death ligand 1 (PD-L1) inhibitor in patients with breast cancer: A systematic review and meta-analysis
by: Lijuan Guo, et al.
Published: (2024-04-01)

Deubiquitination and stabilization of programmed cell death ligand 1 by ubiquitin‐specific peptidase 9, X‐linked in oral squamous cell carcinoma
by: Wu Jingjing, et al.
Published: (2018-08-01)

Programmed death-ligand 1 expression and its correlation with clinicopathological parameters in gallbladder cancer
by: Ji Hye Kim, et al.
Published: (2020-03-01)

Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer
by: Andrzej Kowalski, et al.
Published: (2021-07-01)

Prognosis-related novel immunostaining pattern for programmed cell death ligand 1 and prognostic value of tumour-infiltrating lymphocytes in triple-negative breast cancer
by: Pınar Savaş, et al.
Published: (2023-06-01)

Prognostic Value of Programmed Cell Death 1 Ligand-1 in Patients With Bone and Soft Tissue Sarcomas: A Systemic and Comprehensive Meta-Analysis Based on 3,680 Patients
by: Feng Wang, et al.
Published: (2020-06-01)

The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes
by: Xing-Chen Ding, et al.
Published: (2020-10-01)

Anti-Bovine Programmed Death-1 Rat–Bovine Chimeric Antibody for Immunotherapy of Bovine Leukemia Virus Infection in Cattle
by: Tomohiro Okagawa, et al.
Published: (2017-06-01)

The effect of redox bacteria on the programmed cell death-1 cancer immunotherapy
by: Majid Nejati, et al.
Published: (2024-01-01)

Computational Investigations on the Natural Small Molecule as an Inhibitor of Programmed Death Ligand 1 for Cancer Immunotherapy
by: Geethu S Kumar, et al.
Published: (2022-04-01)

Programmed Cell Death-Ligand 1 Expression Status in Urothelial Carcinoma According to Clinical and Pathological Factors: A Multi-Institutional Retrospective Study
by: Hyung Suk Kim, et al.
Published: (2020-10-01)

Correlation between estrogen receptor and programmed death ligand-1 in type I endometrial cancer
by: Setyo Teguh Waluyo, et al.
Published: (2024-03-01)

Development of a microcantilever-based biosensor for detecting Programmed Death Ligand 1
by: Tajweed Neairat, et al.
Published: (2024-06-01)